Role of tumor necrosis factor-alpha and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women.
Walsh
B W
BW
Brigham and Women's Hospital, Boston, Massachusetts 02115, USA. BWWALSH@BICS.BWH.HARVARD.EDU
Cox
D A
DA
Sashegyi
A
A
Dean
R A
RA
Tracy
R P
RP
Anderson
P W
PW
D000704:Analysis of Variance; D002097:C-Reactive Protein / Q000378:metabolism*; D002318:Cardiovascular Diseases / Q000097:blood / Q000209:etiology*; D004311:Double-Blind Method; D004797:Enzyme-Linked Immunosorbent Assay; D004965:Estrogen Antagonists / Q000627:therapeutic use*; D005260:Female; D020249:Hormone Replacement Therapy / Q000009:adverse effects*; D006801:Humans; D015850:Interleukin-6 / Q000097:blood*; D008875:Middle Aged; D010024:Osteoporosis / Q000097:blood / Q000188:drug therapy*; D017698:Postmenopause; D011446:Prospective Studies; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use*; D012307:Risk Factors; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism*
D004965:Estrogen Antagonists; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D020849:Raloxifene Hydrochloride; D002097:C-Reactive Protein